PRNewsWire
06 Mar 2026, 13:35 UTC · 34w ago
Verdict
Headline takes no side. We score MREO −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Two Phase 3 studies of Mereo BioPharma's setrusumab failed to meet their primary endpoints of reducing annualized clinical fracture rates versus placebo and bisphosphonates, respectively.
So whatThe complete failure of both pivotal Phase 3 trials on their primary endpoints fundamentally undermines the drug's commercial viability and core asset value, driving an 87% stock crash.
More negative than 99% of claims this week
Mereo's stock price fell 87.64%, closing at $0.28 per share on December 29, 2025, following the announcement of the Phase 3 trial failures.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 99% of claims this week
A federal securities class action has been filed against Mereo, alleging the company made false or misleading statements regarding the Phase 3 ORBIT and COSMIC programs, with a lead plaintiff deadline of April 6, 2026.
More negative than 94% of claims this week
Both Phase 3 setrusumab trials demonstrated statistically significant improvements in bone mineral density on secondary endpoints with no new safety concerns identified.
More positive than 60% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company is facing a securities class action lawsuit following a massive stock price drop due to failed Phase 3 clinical trials.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
3h ago
−25.6%
Price agrees with the score
$0.2910 vs $0.3910 close before publication (Mar 5) · not market-adjusted
MREO chart →
